Boster Immunoleader

antibody

Anti-Caspase-12 Antibody

PA2103

100 ug/vial

200 USD

polyclonal

rabbit

western blot, immunohistochemistry - paraffin section

Anti-Caspase-12 Antibody

PA2103

Polyclonal

Rabbit IgG polyclonal antibody for Inactive caspase-12(CASP12) detection. Tested with WB, IHC-P in Human.

200 USD

Rabbit IgG

100 ug/vial

Lyophilized

No cross reactivity with other proteins.

Reacts with: human

WB,IHC-P

Concentration: 0.1-0.5μg/ml; Tested Species: Human

Concentration: 0.5-1μg/ml; Tested Species: Human

WB: The detection limit for CASP12 is approximately 0.5ng/lane under reducing conditions. Tested Species: In-house tested species with positive results. Predicted Species: Species predicted to be fit for the product based on sequence similarities. By Heat: Boiling the paraffin sections in 10mM citrate buffer, pH6.0, for 20mins is required for the staining of formalin/paraffin sections. Other applications have not been tested. Optimal dilutions should be determined by end users.

A synthetic peptide corresponding to a sequence at the N-terminus of human Caspase-12(71-84aa KIFREHLWNSKKQL).

Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg Thimerosal, 0.05mg NaN3.

Immunogen affinity purified.

Add 0.2ml of distilled water will yield a concentration of 500ug/ml.

At -20˚C for one year. After reconstitution, at 4˚C for one month. It can also be aliquotted and stored frozen at -20˚C for a longer time. Avoid repeated freezing and thawing.

Boster provides a series of assays reacted with primary antibodies. Antibody can be supported by chemiluminescence kit EK1002 in WB, supported by SA1022 in IHC(P).

Caspase 12 is an enzyme known as a cysteine protease. It belongs to a family of enzymes called caspases that cleave their substrates at C-terminal aspartic acid residues. The CASP12 gene was mapped to chromosome 11q22.3. Csp12L attenuates the inflammatory and innate immune response to endotoxins and in doing so may constitute a risk factor for developing sepsis. The estrogen-mediated inhibition of CSP12L expression is a built-in mechanism that has evolved to protect females from infection by favoring a more robust inflammatory response to pathogens, perhaps notably in childbirth.

1. Fischer, H., Koenig, U., Eckhart, L., Tschachler, E. Human caspase 12 has acquired deleterious mutations. Biochem. Biophys. Res. Commun. 293: 722-726, 2002. 2. Saleh, M., Mathison, J. C., Wolinski, M. K., Bensinger, S. J., Fitzgerald, P., Droin, N., Ulevitch, R. J., Green D. R., Nicholson, D. W. Enhanced bacterial clearance and sepsis resistance in caspase-12-deficient mice. Nature 440: 1064-1068, 2006. 3. Yeretssian, G., Doiron, K., Shao, W., Leavitt, B. R., Hayden, M. R., Nicholson, D. W., Saleh, M. Gender differences in expression of the human caspase-12 long variant determines susceptibility to Listeria monocytogenes infection. Proc. Nat. Acad. Sci. 106: 9016-9020, 2009.

CASP12

Inactive caspase-12

caspase 12(gene/pseudogene)

Apoptosis related cysteine protease antibody CASP 12 antibody CASP-12 antibody casp12 antibody CASP12P1 antibody caspase 12(gene/pseudogene) antibody caspase 12 pseudogene 1 antibody Caspase 12 psuedogene 1 antibody Caspase12 antibody CASPC_HUMAN antibody Inactive caspase-12 antibody OTTHUMP00000207032 antibody UNQ9415 antibody

Q6UXS9